Akardo AB

At Akardo AB in Stockholm, a major focus is on cardiovascular diseases, including atherosclerotic cardiovascular disease, hypertension, atrial fibrillation, and heart failure. These studies are designed to test new treatments and assess whether they can lower the risk of serious heart and stroke-related events.

• Research on atherosclerotic cardiovascular disease and primary prevention in people at high risk
• Studies in atrial fibrillation aimed at reducing stroke risk
• Trials in heart failure and cardiomyopathy to improve outcomes and symptoms
• Evaluation of therapies intended to prevent major cardiovascular events

Overall, the site is active in developing and evaluating therapies that may help prevent heart attacks, strokes, and worsening heart disease.

Another important area of research at this hospital/clinic is nutritional and metabolic diseases, especially mixed dyslipidemia, hypertriglyceridemia, and inherited cholesterol disorders such as heterozygous familial hypercholesterolaemia. The trials are focused on improving lipid control and evaluating whether newer therapies can better reduce long-term cardiovascular risk.

• Studies in mixed dyslipidemia and severe triglyceride elevation
• Research on inherited and high-risk cholesterol disorders
• Testing treatments aimed at lowering harmful blood lipids
• Assessment of whether lipid-lowering strategies can prevent future cardiovascular events

This work highlights a strong interest in both treatment effectiveness and prevention for people with difficult-to-control lipid disorders.

The site also conducts clinical trials in respiratory tract diseases, especially chronic obstructive pulmonary disease. These studies explore new options for reducing flare-ups, improving breathing-related outcomes, and easing the burden of moderate to very severe disease.

• Trials in COPD and frequent exacerbations
• Research on treatments for patients with more advanced respiratory symptoms
• Evaluation of therapies designed to reduce exacerbations and improve daily function
• Studies looking at broader cardiopulmonary outcomes in lung disease

These investigations aim to improve both symptom control and long-term disease management for people living with chronic lung conditions.

Nervous system diseases are represented through trials in migraine, including attacks with and without aura. The studies are focused on testing treatments for both prevention and acute relief, with the goal of improving quality of life for people affected by recurring headaches.

• Research in migraine prevention for adults with inadequate response to prior therapies
• Studies of treatments for acute migraine relief
• Evaluation of options for migraine with or without aura
• Work aimed at reducing migraine frequency and pain burden

These trials reflect a practical focus on better control of migraine symptoms and fewer disabling attacks.

Akardo AB is also involved in research on immune system diseases and virus diseases, including herpes zoster and inflammatory conditions linked to COPD. This area includes studies of vaccines and biologic therapies intended to prevent infection or reduce inflammation-driven disease activity.

• Vaccine research for herpes zoster prevention
• Studies of biologic treatments in inflammatory respiratory disease
• Evaluation of immune-targeted therapies to improve disease control
• Work aimed at preventing infection and reducing flare-related complications

These trials show a broad interest in immune-based approaches across both infectious and chronic inflammatory diseases.

Across several studies, the Akardo MedSite supports research into newer therapies for people with combined cardiometabolic risk, including hypertension, high cardiovascular risk, and conditions linked to future heart failure. The purpose is to determine whether emerging treatments can improve outcomes in patients who remain at risk despite standard care.

• Trials in hypertension with elevated cardiovascular risk
• Studies aimed at preventing heart failure and cardiovascular death
• Research on therapies for patients with established vascular disease
• Evaluation of treatment effectiveness in high-risk cardiometabolic populations

This research portfolio combines prevention, symptom control, and long-term risk reduction across multiple chronic diseases.